Physician profile
Muhammad A Jadoon
NPI 1730390170
$2,836.98
in general payments reported to CMS, 2019-2025
25 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $66.27 · 2021: $71.85 · 2022: $436 · 2023: $849 · 2024: $623 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $517.99 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $474.47 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $378.70 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Dexcom, INC. | $285.34 | 2022-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Amgen INC. | $196.11 | 2019-2024 | Repatha, Prolia, Evenity |
| Medtronic, INC. | $195.41 | 2024-2025 | Minimed 780g |
| Lilly USA, LLC | $138.81 | 2021-2025 | Kisunla, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $130.20 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Insulet Corporation | $81.42 | 2022-2024 | Omnipod |
| Pfizer INC. | $81.19 | 2025 | |
| Supernus Pharmaceuticals, INC. | $42.97 | 2024 | Qelbree |
| Kowa Pharmaceuticals America, INC. | $40.11 | 2024 | Zoryve |
| Tandem Diabetes Care, INC. | $36.57 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $32.84 | 2023 | |
| Sanofi-Aventis U.S. LLC | $30.22 | 2019-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $24.35 | 2023 | Gvoke Hypopen |
| Genentech USA, INC. | $24.23 | 2019 | |
| Sumitomo Pharma America, INC. | $19.30 | 2025 | Gemtesa |
| Ardelyx, INC. | $19.13 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.67 | 2025 | Xifaxan |
| Corcept Therapeutics | $15.61 | 2025 | Korlym |
| Abbott Laboratories | $15.34 | 2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $13.91 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.46 | 2023 | Jardiance |
| Allergan, INC. | $11.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Jadoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.